Repeated supratherapeutic dosing of strontium ranelate over 15 days does not prolong QTc interval in healthy volunteers

Jorg Taubel,1 Asif Naseem,1 Duolao Wang,2 Radivoj Arezina,1 Ulrike Lorch1 & A. John Camm3

1Richmond Pharmacology Ltd, St George’s University of London, Cranmer Terrace, London, 2Department of Epidemiology & Population Health, London School of Hygiene & Tropical Medicine, Keppel Street, London and 3Department of Cardiological Sciences, St George’s University of London, Cranmer Terrace, London, United Kingdom

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT

- Strontium ranelate 2 g (granule form) oral suspension, is an anti-osteoporotic treatment which is available in European countries.
- Repeated administration of strontium ranelate (4 g day−1) was found to be clinically and biologically well tolerated by healthy post menopausal women volunteers.
- Strontium is a bivalent cation with strong affinity for bone and which in certain conditions has a metabolism similar to that of calcium. In terms of importance, calcium has a major role in the electrophysiology of cardiac muscle and ECG abnormalities are known to be due to changes in plasma calcium concentrations.
- Although no signal was observed in pre-clinical or clinical studies, the safety of strontium ranelate in accordance with the ICH – E14 guidelines needed to be assessed in order to characterize the effect on QTc of repeated oral doses of strontium ranelate (4 g day−1).

WHAT THIS STUDY ADDS

- This thorough QT/QTc study directly compared supratherapeutic repeat doses of strontium ranelate (4 g day−1 for 15 days) with placebo on the largest time-matched mean QTc variation, from baseline to under treatment values, in healthy subjects.
- The largest time-matched difference in QTcI compared with placebo was observed at 1 h post dose (mean [90% CI] 7.54 [5.17, 9.90] ms). No subject had a QTc greater than 480 ms during the study. Both moxifloxacin and strontium ranelate were well tolerated in healthy subjects.

AIMS

The study was performed to assess the safety of strontium ranelate in accordance with the ICH, E14 guidelines for QT/QTc studies. Its primary objective was to compare supratherapeutic repeated dosing of strontium ranelate (4 g day−1 for 15 days) with placebo on the largest time-matched mean QTc variation, from baseline to under treatment values, in healthy subjects.

METHODS

Ninety-six healthy male and female subjects (27.7 ± 7.5 years) were included to receive 1 day of placebo followed by 15 days of supratherapeutic repeated dosing of strontium ranelate (4 g day−1), in a 4 month, randomized, placebo (16 days) and positive-controlled (single dose of moxifloxacin 400 mg preceded by 15 days of placebo), double-blind, double dummy, crossover design. Measurement of QT interval was performed automatically on the ECGs with subsequent manual onscreen over-reading by cardiologists using electronic callipers.

RESULTS

The largest time-matched difference in QTcI (individual QT correction for heart rate) between moxifloxacin 400 mg and placebo was observed at 2 h post dose (mean [95% CI] 10.62 [7.90, 13.35] ms). For strontium ranelate (4 g day−1) the largest time-matched difference in QTcI compared with placebo was observed at 1 h post dose (mean [90% CI] 7.54 [5.17, 9.90] ms). No subject had a QTc greater than 480 ms during the study. Both moxifloxacin and strontium ranelate were well tolerated in healthy subjects.

CONCLUSIONS

The findings of this study demonstrate that the administration of supratherapeutic repeated oral doses of strontium ranelate (4 g day−1 for 15 days) does not lead to a prolongation of the QT/QTc interval above the threshold of regulatory concern.